Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imunon's change in receivables for the quarter that ended in Jun. 2026 was €0.00 Mil. It means Imunon's Accounts Receivable
stayed the same
from Mar. 2026 to Jun. 2026 .
Imunon's change in receivables for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means Imunon's Accounts Receivable
stayed the same
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Imunon's liquidation value for the
three
months ended in Jun. 2026 was €-3.42 Mil.
Imunon (FRA:CBO0) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Imunon's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imunon Change In Receivables Related Terms
Imunon Change In Receivables Historical Data
* Premium members only.
The historical data trend for Imunon's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of €0.00 Mil mean?
Imunon (FRA:CBO0) has a Change In Receivables of €0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Imunon and its competitors.
Is Imunon's Change In Receivables too high?
Imunon's current Change In Receivables is €0.00 Mil. Overall, Imunon has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Imunon's Change In Receivables compare to CVKD and RVPH?
Imunon's Change In Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Imunon and its competitors. Imunon's current Change In Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Based on GuruFocus' analysis, Imunon (FRA:CBO0) is currently considered Possible Value Trap. The stock's GF Value™ is €5.35, compared to a current price of €1.26 — trading 76.4% below its estimated fair value. The current Change In Receivables is €0.00 Mil. Imunon's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Imunon (FRA:CBO0), the current Change In Receivables is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imunon (FRA:CBO0) Overvalued in 2026?
Based on GuruFocus' analysis, Imunon stock appears to be undervalued.
The current stock price of €1.26 is trading 76.4% below its estimated GF Value™ of €5.35.
GuruFocus considers Imunon to be Possible Value Trap.
Key valuation signals for FRA:CBO0:
Change In Receivables: €0.00 Mil
GF Value™: €5.35 vs. price of €1.26 (76.4% below fair value)
No single metric tells the full story. See the FRA:CBO0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
37GF Score
Get the complete analysis for FRA:CBO0
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CBO0 has been successfully added to your 
